



ABL, Inc. Acquires Majority Interest in Platine Pharma Services

2014.07.22

Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies. Platine provides immunologic expertise and services using a broad range of in vitro platforms such as flow cytometry, ELISpot, ELISA, multiplex, Singulex™, and MSD® capabilities. Platine also offers its Immuno'line™ T-cell activation service, a unique approach to assess the specific immune response to a particular therapeutic drug, vaccine, cosmetic, or food product of interest.

Dr. Thomas VanCott, President and CEO of ABL, commented on the acquisition stating, "We are extremely excited to have the Platine organization join ABL. Over the years, their staff of dedicated and highly talented scientists has proven their ability to deliver the highest quality of service, meeting clients' immunological testing needs throughout the product development process. "This acquisition also represents a significant step in the strategic growth of ABL, providing a European-based facility for clinical and other sample processing and immunomonitoring analyses. With laboratories based in France and the U.S., ABL is better positioned to support our clients' increasingly global clinical development strategies. ABL now offers a synergistic core of immunoassay expertise that provides both U.S. and international clients a more integrated laboratory solution."

"This is a new important step for the development of Platine's offerings", added Stéphane Legastelois, CEO of Platine Pharma Services. "After the acquisition of the Immunoassay and Immunogenicity activities from Indicia biotechnology, Platine defines itself as a provider of a comprehensive range of immune information to the Pharmaceutical and Diagnostic industries. The acquisition by ABL, Inc. puts Platine in an optimal competitive position for both US and European markets."

About ABL, Inc. ABL, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including

government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical studies, clinical immunomonitoring and immunogenicity testing, and Phase I/II cGMP biologics manufacturing. Since 2001, ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at <http://www.ablinc.com/>. About Platine Pharma Services Founded in 2011 and based in Lyon within the Infectious Disease Center, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays highlighting key immune markers in both normal and pathological conditions. This information guides healthcare professionals at each step of the development of prophylactic or therapeutic drugs against cancers, infectious and inflammatory diseases. For more information: www.platine-lab.com.